Trials / Recruiting
RecruitingNCT07154264
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
A Phase 2 Study of DZD8586 Combination Therapy in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- Dizal (Jiangsu) Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2 study to investigate the efficacy and safety of DZD8586 in combination in participants with CLL/SLL. This study consists of two parts: Part A is the safety lead-in phase, and Part B is the dose expansion phase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DZD8586 | DZD8586 will be taken orally once daily on days 1-28 of each cycle. |
| DRUG | Venetoclax | Venetoclax will be taken orally once daily on days 1-28 starting from cycle 4 day 1. |
Timeline
- Start date
- 2025-09-22
- Primary completion
- 2029-12-01
- Completion
- 2030-01-01
- First posted
- 2025-09-04
- Last updated
- 2025-12-24
Locations
15 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07154264. Inclusion in this directory is not an endorsement.